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ABSTRACT
Introduction: Vaccination against varicella rapidly reduces disease incidence, resulting in reductions in
both individual burden and societal costs. Despite these benefits, there is no standardization of varicella
immunization policies in Europe, including countries in Central and Eastern Europe (CEE).
Areas covered: This systematic literature review identified publications on the epidemiology of
varicella, its associated health and economic burden, and vaccination strategies within the CEE region,
defined as Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary,
Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, and Slovenia. Twenty-six studies were identified
from a search of PubMed, Embase®, and MEDLINE® biomedical literature databases, supplemented by
gray literature and country-specific/global websites.
Expert commentary: Limited information exists in published studies on the burden of varicella in CEE.
The wide variability in incidence rates between countries is likely explained by a lack of consistency in
reporting systems. Funded universal varicella vaccination (UVV) in CEE is currently available only in Latvia
as a one-dose schedule, but Hungary together with Latvia are introducing a two-dose strategy in 2019.
For countries that do not provide UVV, introduction of vaccination is predicted to provide substantial
reductions in cases and rates of associated complications, with important economic benefits.
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Varicella is a highly contagious disease. In a country with no
vaccination program, the majority of incident cases (52‒78%)
occur in children aged under 6 years, rising to 89‒96% in
those aged under 12 years [1]. A systematic literature review
(SLR) examining varicella disease burden across 31 European
countries estimated a total of 5.5 million varicella cases
annually before the introduction of childhood immunization,
including 3 million cases in children aged under 5 years [2]. In
Central and Eastern Europe (CEE) in particular, annual inci-
dences of community varicella in children aged under 5
years ranged from 7108 per 100,000 same-age cohort in
Romania to 11,640 per 100,000 in Slovenia [2]. Incidences of
varicella-related hospitalizations in CEE were also highest in
this age group, ranging from 22–27 per 100,000 children of
the same age in Romania to 36–44 per 100,000 in Slovenia [2].
While varicella is usually a mild or moderate illness [1–4],
a small proportion of varicella cases are serious, including com-
plications such as superinfection of the skin or soft tissue,
respiratory syndromes, and neurological manifestations (e.g. cer-
ebellar ataxia, encephalitis) [1,5]. Risk of serious varicella infec-
tion, or even death, is higher in young children, the elderly,
immunocompromised individuals, and those with underlying
health issues [1]. However, the susceptibility of even healthy
children to complications of varicella emphasizes the importance
of recognizing the disease as a health priority [6].
Vaccination against varicella reduces the number, size, and
duration of varicella outbreaks [1,7] and rapidly reduces disease
incidence over time [6], thereby reducing societal and financial
costs [5]. Despite these benefits, there is no consensus across
Europe on varicella immunization policy [6]. Within CEE, only
Cyprus, Czech Republic, and Latvia recommend universal varicella
vaccination (UVV) for all children [8] and, of these, only Latvia has
a state-provided one-dose varicella immunization program. In
addition to Latvia, Hungary recently announced the introduction
of a two-dose funded vaccination strategy in 2019 [9]. A number
of other CEE countries endorse vaccination only for susceptible
(medical or occupational) at-risk groups [1]. Barriers to the
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adoption of a UVV program among children include the public
perception of varicella as a generally mild disease, cost, the risk of
an increase in herpes-zoster incidence among those not vacci-
nated against varicella or herpes zoster predicted inmultidisciplin-
ary studies [10–14], and a temporary increase in herpes zoster
cases following reduced circulation of varicella zoster virus under
the influence of a UVV program (‘exogenous boosting’ hypothesis)
[7,15,16]. The lack of availability of a registered varicella vaccine
within some CEE countries – Bulgaria, for example – can also act as
a barrier.
The burden of varicella on public health has not been well
studied in CEE, and gaps in evidence can delay policy deci-
sions on vaccination. This SLR examines the available evidence
on the epidemiology of varicella in CEE, its attributable health
and economic burden including health care resource utiliza-
tion, and data pertaining to varicella vaccination programs in
CEE, with the objective to improve the understanding, preven-
tion, and management of varicella across the region.
2. Methods
The SLR was performed following guidance issued by the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA; www.prisma-statement.org). A search of bio-
medical literature databases (PubMed, Excerpta Medica
Database [Embase®], Medical Literature Analysis, and Retrieval
SystemOnline [MEDLINE®]) was conducted from database incep-
tion to 1 February 2016 (the date of the literature search) to
identify relevant English-language publications (Table 1).
The current review focusesonpublications from theCEE region:
Albania, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech
Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania,
Serbia, Slovakia, and Slovenia. This CEE analysis forms part of
a wider review that includes regions from Latin America, the
Middle East, andAsia-Pacificwith the aim togain anunderstanding
of trends around the world.
A supplementary gray literature search, performed under the
guidance of local key opinion leaders, identified published and
unpublished data from other sources, including non-English lan-
guage literature, government reports, PhD theses, European sur-
veillance programs, health bulletins, and the Institute for Health
Metrics and Evaluation (IHME) website. Searches were also
conducted on country/region-specific websites, including those
from the European Centre for Disease Prevention and Control
(http://ecdc.europa.eu/), Bulgaria (http://www.ncipd.org/; http://
ncpha.government.bg/index.php?option=com_content&view=
article&id=519:morbidity-of-population&catid=372&Itemid=
656&lang=en), Croatia (https://www.hzjz.hr/en/cat/news/), Czech
Republic (http://www.szu.cz/), Hungary (http://www.oek.hu/),
Latvia (https://www.spkc.gov.lv/), Lithuania (http://www.ulac.lt),
Poland (http://www.gis.gov.pl/), Romania (https://cnscbt.ro),
Slovakia (http://www.uvzsr.sk/; http://www.epis.sk/), Slovenia
(http://www.nijz.si/), and the World Health Organization (WHO;
http://www.who.int/).
2.1. Study selection and data extraction
Studies identified in the literature search were screened for
inclusion based on predefined eligibility criteria. Studies were
eligible for inclusion if they: (1) included males or females of
any age and race who had primary and/or breakthrough
varicella or were undergoing serological testing for antibodies
to varicella; (2) assessed the epidemiological and/or economic
burden of varicella; and (3) were of the following study design
or study type: epidemiological, cohort, case-control, cross-
sectional, or registry/database. Cost studies/surveys/analyses,
budget impact models, database cost studies, resource-use
studies, and cost-of-illness studies; cost-effectiveness, cost-
utility, cost-benefit, cost-minimization, and cost-consequence
analyses; and routine surveillance reports were also included.
Publications were initially screened for inclusion based on title
and abstract; full-text copies of potentially eligible studies were
subsequently reviewed. First and second screeningprocesseswere
undertaken by a single reviewer. A second independent reviewer
validated a random sample of 20% of studies from both first
and second screenings. There were no cases of disagreement in
ranking between the first and second reviewers.
Cost data were adjusted to 2017 US dollars (USD) and euros by
initially using annual inflation rates to obtain 2017 costs in country-
specific currencies and subsequently converting all costs to USD
and euros based on 2017-dated exchange rates using country-
specific websites. For studies where cost-year was not mentioned,
the publication year was considered as the cost-year for all
calculations.
3. Results
3.1. Studies included in the analysis
In the wider review of Latin America, the Middle East, CEE, and
Asia-Pacific, a total of 4809 records were identified from literature
databases. Of these, 210 studies were identified for inclusion in the
overarching SLR after screening the records based on eligibility
criteria (Figure 1). The majority of studies provided evidence on
Asia-Pacific and theMiddle East, while 26 studieswere identified as
relevant to CEE. Studies described in this review are summarized in
Table 2.
3.2. Epidemiology
A total of 17 studies from CEE included data on the epidemiology
of varicella. All were observational and reported outcomes includ-
ing seroprevalence (5 studies) [17–21], incidence (10 studies)
Article highlights
● Limited information exists in published studies on the burden of
varicella in Central and Eastern Europe.
● The wide variability in reported incidence rates between countries is
likely explained by a lack of consistency in reporting systems.
● Funded universal varicella vaccination (UVV) in the CEE region is
currently available only in Latvia as a one-dose schedule, but
Hungary together with Latvia are introducing a two-dose strategy
in 2019.
● For countries that do not provide UVV, the introduction of vaccina-
tion is predicted to provide substantial reductions in cases and rates
of associated complications, with important economic benefits.
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[17,20,22–29], complications (7 studies) [17,22,25,26,30–32], and
mortality (2 studies) [21,28].
3.2.1. Seroprevalence
Seroprevalence data were provided in studies from Slovenia
[19,20], Albania [17], Croatia [21], and Poland [18]. The
available seroprevalence data varied substantially across
these countries due to different age ranges and assay meth-
ods, ranging from 31% in Albania (predominantly among
children aged 1–14 years) [17] to 98% in Slovenia (among
students aged 18–32 years) [19]. The use of different assay
methods may have influenced these outcomes, with the
Table 1. Search strategy in Embase® and MEDLINE® using Embase.com platform.
No. Query Description Results
#1 ‘chickenpox’/exp OR varicella:ab,ti OR ‘chicken pox’:ab,ti OR ‘chickenpox’:ab,ti Disease facet 20,475
#2 ‘epidemiology’/exp OR epidemi*:ab,ti OR inciden*:ab,ti OR prevalence:ab,ti Epidemiology studies facet 3,251,887
#3 #1 AND #2 Combining disease and epidemiology facets 4778
#4 #3 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/
lim OR [review]/lim)
Excluding reviews, letters, commentary, and searches 1177
#5 #3 NOT #4 3601
#6 #5 AND [2012–2016]/py Studies for all the key regions of interest will be included post-
2012: Latin America, Middle East, Eastern Europe, and Asia-
Pacific
1046
#7 #5 AND [<1966–2011]/py Excluding studies prior to 2012 in countries already covered in
previous review
2549
#8 argentina OR australia OR brazil OR canada OR chile OR china OR india OR
israel OR japan OR korea OR malaysia OR mexico OR ‘new zealand’ OR
philippines OR russia OR ‘saudi arabia’ OR ‘south africa’ OR taiwan OR
thailand OR vietnam OR ‘czech republic’ OR czechoslovakia OR england OR
france OR hungary OR ireland OR poland OR scotland OR ‘slovak republic’
OR slovenia OR turkey OR uk OR ‘united kingdom’ OR wales
15,235,019
#9 #7 NOT #8 1137
#10 #6 OR #9 Final epidemiology review number 2183
#11 ‘economics’/de OR ‘economic aspect’/de OR ‘cost’/de OR ‘health care cost’/de
OR ‘drug cost’/de OR ‘hospital cost’/de OR ‘health economics’/de OR
‘pharmacoeconomics’/de OR ‘economic evaluation’/exp OR
‘socioeconomics’/de OR ‘health care financing’/de OR ‘low cost’ OR ‘high
cost’ OR health*care NEXT/1 cost* OR ‘health care’ NEXT/1 cost* OR cost
NEXT/1 estimate* OR ‘fee’/exp OR ‘budget’/exp OR ‘cost variable’ OR unit
NEXT/1 cost* OR economic*:ab,ti OR pharmacoeconomic*:ab,ti OR ‘hospital
finance’/de OR ‘financial management’/de OR price*:ab,ti OR pricing:ab,ti OR
cost* NEAR/3 (treat* OR therap*) OR ‘cost-effectiveness’ OR ‘cost-utility’ OR
‘cost utility’ OR ‘cost benefit’ OR ‘cost minimisation’ OR ‘cost minimization’
OR ‘budget impact’ OR ‘cost consequence’ OR ‘health care utilization’/de OR
health*care NEXT/1 (utilisation OR utilization) OR ‘health care’ NEXT/1
(utilisation OR utilization) OR resource NEXT/1 (utilisation OR utilization OR
use) OR cost*
Economic burden facet 1,418,584
#12 #1 AND #11 Combining disease and economic facets 1391
#13 #12 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/
lim OR [review]/lim)
Excluding reviews, letters, commentary, and searches 561
#14 #12 NOT #13 830
#15 #14 AND [2012–2016]/py Studies for all the key regions of interest will be included post-
2012: Latin America, Middle East, Eastern Europe, and Asia-
Pacific
223
#16 #14 AND [<1966–2011]/py Excluding studies prior to 2012 in countries already covered in
previous review
606
#17 argentina OR australia OR brazil OR canada OR chile OR china OR india OR
israel OR japan OR korea OR malaysia OR mexico OR ‘new zealand’ OR
philippines OR russia OR ‘saudi arabia’ OR ‘south africa’ OR taiwan OR
thailand OR vietnam OR ‘czech republic’ OR england OR france OR hungary
OR ireland OR poland OR scotland OR ‘slovak republic’ OR slovenia OR
turkey OR uk OR ‘united kingdom’ OR wales
15,141,096
#18 #16 NOT #17 275
#19 #15 OR #18 Final economic review number 498
#20 ‘vaccination’/exp OR ‘immunization’/exp OR immunisation:ab,ti OR
immunization:ab,ti
Vaccination facet 267,250
#21 #1 AND #20 Combining disease and vaccination facets 5137
#22 #21 AND ([conference review]/lim OR [editorial]/lim OR [letter]/lim OR [note]/
lim OR [review]/lim)
Excluding reviews, letters, commentary, and searches will
include all countries 2012 onward
1853
#23 #21 NOT #22 3284
#24 #23 AND [2012–2016]/py Studies for all the key regions of interest will be included post-
2012: Latin America, Middle East, Eastern Europe, and Asia-
Pacific
932
#25 #23 AND [<1966–2011]/py Excluding studies prior to 2012 in countries already covered in
previous review
2345
#26 argentina OR australia OR brazil OR canada OR chile OR china OR india OR
israel OR japan OR korea OR malaysia OR mexico OR ‘new zealand’ OR
philippines OR russia OR ‘saudi arabia’ OR ‘south africa’ OR taiwan OR
thailand OR vietnam OR ‘czech republic’ OR Czechoslovakia OR england OR
france OR hungary OR ireland OR poland OR scotland OR ‘slovak republic’
OR slovenia OR turkey OR uk OR ‘united kingdom’ OR wales
15,141,096
#27 #25 NOT #26 1196
#28 #27 OR #24 Final number for vaccination objective 2128
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Slovenian and Polish teams using the Enzygnost anti-varicella
zoster virus/immunoglobulin G assay (Dade Behring, Marburg,
Germany) [18–20], the Croatian team adopting the Virotech
assay (Russelsheim, Germany) [21], and the Albanian team
using an IgM ELISA [17].
Overall, seroprevalence was age-dependent. For children in
the Polish and Slovenian populations, seroprevalence was
high during the first 6 months following birth (likely due to
maternal antibodies), fell between 6 and 12 months, and
increased steadily thereafter [18,20]. Seroprevalence was com-
parable between males and females [18,20]. Among adults in
Croatia, there was a nonlinear increase in seroprevalence with
increasing age, from 79% in those aged 16–20 years to 94% in
41–45-year-olds (Figure 2) [21].
3.2.2. Varicella incidence
All CEE countries that are members of the European Union/
European Economic Area (EU/EEA) have implemented man-
datory reporting of varicella [24,33–35]. However, there is
no standardized case definition of varicella across the EU/
EEA [36] and, consequently, obtaining reliable inter-country
data on the incidence and burden of varicella is challen-
ging [36].
A 2010 study by the European surveillance network for
selected vaccine-preventable diseases (EUVAC; now hosted
by the European Centre for Disease Prevention and Control
[ECDC]) reported varicella incidence data in countries with
mandatory reporting [24]. Poland, Czech Republic, Estonia,
and Slovenia had the highest reported incidence rates, at
481, 459, 459, and 444 cases per 100,000 inhabitants, respec-
tively, while Cyprus had the lowest incidence at 9 per 100,000
inhabitants (Figure 3). However, a study that attempted to
estimate incidence rates from extrapolated regional surveil-
lance data indicated that notification efficiency (proportion
of all cases reported) could range anywhere from 1% to 50%
in CEE [2].
Among the publications identified in the current SLR, var-
icella incidence data were provided from Slovenia [20,28,29],
Poland [25,27], Albania [17,26], Croatia [23], and Romania [22].
In Slovenia, the overall incidence of varicella declined during
the prevaccination period from 1979 to 2005, from 815.2 per
100,000 inhabitants during 1979–1998 to 458.9 per 100,000 in
2005; the vaccine was launched in 2006 [28,29,35]. In Poland,
where the varicella vaccine has been available in the private
market since 1999, recommended since 2002, and freely avail-
able to immunocompromised individuals since 2009, varicella
Figure 1. Flow of studies through the review process.
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incidence showed a nonlinear increase from 340.2 per 100,000
inhabitants in 2008 to 448.7 per 100,000 in 2011 [25,27]. The
authors attribute this rise to an improvement in surveillance
methods in later years [27]. A similar trend was observed in
Romania, where the incidence of varicella increased three-fold
between 1986 and 2004 (from 110 per 100,000 to 316 per
100,000) [22]. As in the Polish study, the increase in varicella
incidence can most likely be ascribed to more effective meth-
ods of disease surveillance [22].
In studies across Europe, the incidence of varicella is generally
highest in younger children, aged <9 years [17,22,23,26–29]. In
Latvia, for example, there were a total of 1564 cases of varicella in
2017, including 1462 in children aged 0–17 years; of these, 837
cases were in children aged 1–6 years [37]. The annual peak
incidence occurs during winter (October to January) and spring
(March and April) months [20,23,27,28]. Figure 4 shows the sea-
sonality of varicella in Croatia, a trend representative of other
studies in the analysis [23].
Gray literature sources identified additional cyclical trends in
varicella incidence. In Bulgaria and Slovakia, for example, where
varicella vaccination is neither mandatory nor publicly funded and
Figure 2. Seroprevalence (with 95% confidence intervals) of VZV IgG antibo-
dies* in Croatian women of reproductive age [21].
IgG, Immunoglobulin G; VZV, Varicella zoster virus.*By commercial enzyme-linked immu-
nosorbent assay. n = positive for VZV IgG antibodies; N = total number tested.
Figure 3. Incidence rate of varicella per 100,000 inhabitants in CEE (2000–2010) [24].
CEE: Central and Eastern Europe.
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coverage is low, there are wide variations in annual peaks of
varicella. As an illustration, varicella incidences in Bulgaria in
1980, 1990, 2000, 2010, 2015, and 2016 were 537.2, 418.6, 285.8,
261.8, 345.0, and 455.6 per 100,000 population, respectively [38].
This suggests that a 5-year average of incidences may be a more
reliable measure of overall varicella burden (http://www.epis.sk/;
http://www.ncipd.org/). Lithuania, which introduced universal var-
icella vaccination in 2008, reports a range of annual incidences
from 331.7 cases per 100,000 in 2010 (lowest) to 760.8 cases per
100,000 in 2014 (highest), with a mean annual incidence of 482.2
cases per 100,000 for the period 2007 to 2016 [39].
3.2.3. Complications/mortality
The EUVAC surveillance study describes varicella complication
rates of 0.1% and 0.2% in Slovakia and Slovenia, respectively,
during 2008–2010, and 1.0% and 0.1% in Estonia and Hungary,
respectively, in 2010 [24].
Varicella-associated complications were explored in seven
studies originating from CEE countries, including Albania,
Poland, Bosnia-Herzegovina, Bulgaria, and Romania, in addi-
tion to two national reports from Slovenia and Lithuania
[17,22,25,26,30–32,40,41]. The majority of the studies did not
describe the vaccination status of patients; studies that did so
were conducted on unvaccinated groups [25,31]. Rates of
varicella-associated complications were generally low. The
most common complications affected the respiratory system
(pneumonia, respiratory tract infection, and cough), skin (skin
and soft tissue infections), and hematological and neurological
systems (e.g. cerebellitis, encephalitis, status epilepticus).
Notably, the overwhelming majority of patients who devel-
oped complications were immunocompetent and previously
healthy [25,30]. Neither of the two studies with evidence on
mortality in the CEE region reported any varicella-related
deaths [23,28]. A more recent national report from Lithuania
reports one case of death from varicella in 2016 [40].
Primary varicella is frequently more severe in adults than in
children [42]. Two studies, from Bosnia-Herzegovina and
Romania, respectively, described complications of varicella in
both adult and young populations [22,32]. Incidences of spe-
cific complications appeared to differ according to the age of
the patient. For example, rates of varicella pneumopathy were
higher in adults [32], while bacterial skin infections were more
common in children [22]. In addition, a study from the central
region of Slovenia reported that of the 0.69% of varicella cases
that were hospitalized, predominantly due to complications,
pneumonia was more common in adults while skin and cen-
tral nervous system complications prevailed in children [43].
3.3. Economic burden and health care resource
utilization
3.3.1. Resource use and hospitalization rates
Reliable information on primary care visits for varicella is not
available in all CEE countries. However, data from Hungary for
the period 2011–2015 reveal a substantial disease burden related
to varicella among children, with 87% of outpatients visiting their
doctor at least once and 20% visiting a hospital outpatient
clinic [3].
Nine studies provided evidence on resource use and hos-
pitalization rates in Slovenia [20,28,29], Poland [25,27,31],
Bulgaria [30], and Albania [26]. The EUVAC surveillance study,
mentioned above, described wide variations in hospitalization
rates across CEE. Highest hospitalization rates were reported in
Latvia, the only CEE country with mandatory universal vacci-
nation (Figure 5) [24]; it is possible that stringent medical
practices and prioritization of varicella as a public health con-
cern contribute to the hospitalization rates in Latvia, although
interpretation is complex.
In data available from Poland, Albania, and Bulgaria, themean
length of hospital stay ranged from 5 to 7 days [25,26,30,31].
Hospitalization rates in a Polish population over the period
2007–2011 generally remained constant, ranging from 0.51% to
0.59% [25,27]. In Slovenia, the proportion of varicella cases that
were hospitalized over the period 1996–2005 were highest in
Figure 4. Seasonality of varicella in Croatia (1977–2012). Reproduced, with
permission, from Vjekoslav Bakašun and Đana Pahor, ‘Epidemiological Patterns
of Varicella in the Period of 1977 to 2012 in the Rijeka District, Croatia’,
Epidemiology Research International, vol. 2014, Article ID 193,678 [23].
Figure 5. Percentage of persons of all ages with varicella who were hospitalized
across CEE (2008–2010) [24].
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children under 1 year (19.5 per 1000 varicella patients) and adults
over 30 years (23.3 per 1000), and were lowest in patients aged
10–14 years (3.3 per 1000) [28]. In a study of children and
adolescents in Poland, hospitalization rates were highest during
the first year of life, which the authors ascribe to the common use
of preschool childcare facilities and early exposure to varicella
virus [25].
The use of antibiotics for treating bacterial complications in
pediatric varicella patients is being investigated in the multi-
country MARVEL study, which reports widespread high rates
of inappropriate or unconfirmed antibiotic use [44]. The
authors suggest that wider adoption of UVV would reduce
both the inappropriate as well as appropriate use of antibio-
tics in this population.
3.3.2. Economic burden/economic evaluations
Only one study was identified in the SLR that described the
economic burden of varicella in CEE [45]. This Hungarian
study, utilizing National Health Insurance Fund
Administration data, estimated that the direct and indirect
costs of varicella-related health care provision in 2012 were
almost one billion forint annually (equivalent to approximately
3.8 million USD and 3.4 million euros, 2017-dated).
An economic model using epidemiological data from the
Epidemiological Information System in Slovakia, published in
2000, calculated that a varicella vaccination strategy would
provide total direct and indirect cost savings of 2,751,270.24
USD (equivalent to 2,902,155.88 USD and 2,546,817.89 euros,
2017-dated), a cost-effectiveness ratio of 432.95 USD, calcu-
lated from a numerator of expected changes in the costs of
treatment influenced positively by vaccination and
a denominator of expected improvement in health achieved
by vaccination (456.69 USD and 405.17 euros, 2017-dated),
and a benefit-cost ratio of 0.15 [46].
A cost-benefit study from Slovenia, published in 2002,
which assumed 95% vaccine coverage and 90% efficacy for
a single dose in a hypothetical birth cohort of 5800 children,
estimated a cost-benefit ratio of 0.25 using medical costs and
0.89 using both medical and nonmedical costs [47].
Finally, a recently published paper from Poland reports on the
economic burden of varicella in children aged 1–12 years [48]. In
an analysis of 150 outpatients and 150 inpatients taken from
seven selected physician sites, health care resource utilization
was as follows: over-the-counter medications, 80.0% outpatients
and 81.3% inpatients; prescription medications, 80.0% outpati-
ents and 93.3% inpatients; tests/procedures, 0.0% outpatients
and 69.3% inpatients; and allied health professional consults,
0.0% outpatients and 24.0% inpatients. Total (direct and indirect)
2015-dated cost per varicella case was 5013.3 zloties (PLN)
(13,33.51 USD and 1183.09 euros, 2017-dated) for inpatients
and 1027.2 PLN (273.19 USD and 242.37 euros, 2017-dated) for
outpatients, resulting in an estimated overall annual (2015) cost
of varicella in Poland of 178,198,320 PLN (47,402,920.06 USD and
42,055,693.9 euros, 2017-dated). The authors conclude that
a significant clinical and economic burden is associated with
varicella in Poland.
3.4. Vaccination programs and coverage
WHO guidelines recommend routine childhood immunization
against varicella where high (>80%) and sustained vaccine
coverage can be achieved and where the disease represents
an important public health issue in the context of affordability
[49]. As noted by the European Centre for Disease Prevention
and Control: ‘The experience of outbreaks in vaccinated popu-
lations has shown that varicella vaccination decreases the
number, size and duration of varicella outbreaks and that
decreases were greater with a two-dose schedule’ [1]. In CEE,
only Latvia has introduced a funded UVV program, with
a single-dose regimen for children aged between 12 and
15 months introduced in 2008 and a two-dose regimen with
the second dose at age 7 years commencing in 2019 [24].
A mandatory combined vaccine (measles-mumps-rubella-
varicella) is included in the childhood immunization schedule
for children aged 12–15 months [8,33]. Varicella immunization
coverage in Latvia was 48.1% in 2008, 63.9% in 2009, and
78.9% in 2010 [33]. Recently published data show that vari-
cella coverage in Latvia had increased further to 85.2% in 2017
(www.spkc.gov.lv). Although specific data on the impact of
vaccination in Latvia have not been published, the low inci-
dence of varicella recorded in 2010 (second only to Cyprus)
appears to confirm the effectiveness of vaccination [24].
Additional CEE countries that have adopted varicella vaccina-
tion for susceptible individuals and/or high-risk groups include
Poland (mandatory since 2010) [8,24], Cyprus [8,33,50], Estonia
[24,33], Lithuania [8,50], and Slovenia [33] (Table 3).
In Hungary, varicella vaccination was made available in
2003, but only in the private market. Coverage in Hungary
remains poor [51], although this is expected to improve with
the introduction of a two-dose, funded vaccination strategy
starting in 2019 [9], presumably in accordance with the cur-
rent recommendation of 15 and 18 months of age, although
measles vaccination is given at 15 months and 11 years of age.
Varicella vaccination is available in Lithuania only in the pri-
vate market or in governmental health care institutions where
patients are also required to pay for it. In Slovakia, non-specific
coverage by health-insurance companies can extend to var-
icella vaccination. Moreover, physicians can request vaccina-
tion coverage for certain patients, such as those with
immunodeficiency, before the start of biological therapy.
Recommendations from the Central European Vaccination
Awareness Group, published in 2014, aim to raise awareness
and formalize guidance on immunization in high-risk pediatric
populations across central Europe [52].
4. Conclusion
The impact of varicella and its associated morbidity has, to
date, not been well studied in CEE, which has contributed to
an under-estimation and under-prioritization of varicella as
a public health issue [5,53]. This SLR evaluated published
information on the epidemiology and economic burden of
varicella in CEE and the existing varicella vaccination programs
in this region.
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The study data describe a wide variation in the incidence of
varicella between CEE countries. Several factors are likely to con-
tribute to this variation, including the lack of a standardized case
definition and heterogeneity in the surveillance systems and
reporting rates. The mild nature of varicella in most patients
means that doctors are often not consulted [1] and the lack of
mandatory reporting in somecountries, evenwhenmedical advice
is sought, is likely to contribute to under-reporting of the true
incidence [5].
Limited data availability also precludes an analysis of changes
in varicella incidence following the introduction of vaccination in
CEE. Experience in other geographical regions, such as the United
States and other areas of Europe, is that vaccination provides
highly effective and long-lasting protection, and that a two-dose
strategy is superior to a one-dose approach [54–56]. Latvia is the
only CEE country that provides universal vaccination, currently in
the form of a single dose, while other countries in CEE offer
vaccination limited to at-risk groups or in the private sector. No
CEE countries have yet adopted a two-dose vaccination regimen,
although Latvia and Hungary are doing so from 2019 [9,24].
In conclusion, this SLR assessed published studies on the inci-
dence and burden of varicella in CEE and summarized the vaccina-
tion programs in this region. Despite the dearth of data on varicella
in CEE countries, the evidence from this region – similar to that
from other areas of the world – suggests that introduction of
varicella vaccination programs provides benefit from both patient
and public health perspectives. In order to achieve a full herd
protection effect, such as a reduction of varicella in the unvacci-
nated population <12 months of age, high coverage is required
[57]. In CEE countries, this is traditionally achieved through state-
funded mandatory universal immunization programs.
5. Expert commentary
• What are the key weaknesses in clinical management
so far?
• Lack of:
• dedicated studies examining incidence/societal/
financial impact
• mandatory, standardized surveillance systems
(under-reporting of varicella as an issue)
• European Union case definition
• economic/resource utilization studies
• Inter-country variation in vaccination strategies
• Under-recognition of varicella as a public health
priority
Table 3. Recommendations for varicella vaccination in different CEE populations.
Country Target group
Cyprus ● Children at 13–18 months and at 4–6 years (private sector only)
● Susceptible individuals and/or high-risk groups and susceptible health care workers
Estonia ● Medical-risk group
● Susceptible persons
● Persons with acute lymphocytic leukemia in remission
● Persons with leukemia (recommended for seronegative children aged under 12 years)
● Candidates for organ transplantation (recommended for seronegative children aged under 12 years)
● Persons before chemotherapy (recommended for seronegative children aged under 12 years)
Latvia ● Universal vaccination (single-dose) at 15 months
Lithuania ● Children and susceptible individuals (private sector only)
● Susceptible health care workers
● Before solid organ transplantation with no signs of immunity against varicella
● Household contacts of allogenic bone marrow transplantation recipients
● HIV infected persons with CD4 count >200/mm3
Poland ● Specific-risk group
● Medical-risk group
● Susceptible persons
● Seronegative women of childbearing age
● Immunocompromised persons (mandatory for children aged under 12 years)
● Persons with acute lymphocytic leukemia in remission (mandatory for children aged under 12 years)
● Persons infected with HIV (mandatory for children aged under 12 years)
● Persons before chemotherapy (mandatory for children aged under 12 years)
● Seronegative family members of high-risk children (mandatory for children aged under 12 years)
● Seronegative close contacts of immunosuppressed individuals (mandatory for children aged under 12 years)
Slovakia ● Patients before biological therapy or chemotherapy (e.g. idiopathic bowel diseases, rheumatic diseases, oncologic diseases)
● Candidates for organ transplantation
● Seronegative women with planned pregnancy
● Seronegative close contacts of high-risk patients
● Susceptible health care workers
Slovenia ● Medical-risk group
● Persons with acute lymphocytic leukemia in remission
● Candidates for organ transplantation
● Seronegative family members of high-risk children
● Susceptible health care workers
● Recommended for children who have not had varicella prior to starting immunosuppressive treatment
● Close contacts of immunocompromised individuals
CEE: Central and Eastern Europe; HIV: human immunodeficiency virus.
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• What potential does further research hold? What is the ulti-
mate goal in this field?
• Reduction of the disease burden of varicella through
vaccination
• Widespread availability of fully funded, mandatory
varicella vaccination programs
• What research or knowledge is needed to achieve this goal
and what is the biggest challenge in this goal being achieved?
• Standardization of varicella reporting
• Verification of the effectiveness of the various vaccina-
tion strategies (one dose vs. two doses; universal vac-
cination vs. ‘at-risk’ populations) currently in place
across CEE, and consensus regarding the most efficient
means of reducing the incidence/impact of varicella
• Better understanding of the impact of regional factors
like climate and/or social mixing patterns on seropre-
valence/incidence rates




The literature on the burden of varicella in CEE that is analyzed
in the current systematic review raises a number of interesting
issues. Firstly, there is an important lack of dedicated studies
that examine the incidence and societal/financial impact of
varicella in this region. Mandatory, standardized surveillance
systems are lacking, and there is in consequence an under-
recognition of varicella as a public health priority. Initiatives
from the Central European Vaccination Awareness Group aim
to address this deficit. Secondly, verification of the effective-
ness of vaccination strategies – as has been demonstrated in
other regions of the world – is awaited across CEE. The wider
introduction of universal varicella vaccination, in particular the
two-dose strategy, is predicted to bring important benefits to
CEE from both patient and public health perspectives.
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